Sharad K. Jain
Experienced in Muscle Invasive Bladder Cancer

Dr. Sharad K. Jain

Oncology | Hematology
2600 Scripture St, 
Denton, TX 
On Staff At
Offers Telehealth
Experienced in Muscle Invasive Bladder Cancer
2600 Scripture St, 
Denton, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sharad Jain is a Hematologist and an Oncologist in Denton, Texas. Dr. Jain is rated as an Experienced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Paget Disease of the Breast, Anemia, Lung Cancer, and Pleuropulmonary Blastoma.

His clinical research consists of co-authoring 20 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Maulana Azad Medical College ()
Residency
State University of New York at Buffalo (1990)
Specialties
Oncology
Hematology
Licenses
Internal Medicine in TX
Fellowships
State University of New York at Buffalo (1993)
Hospital Affiliations
Texas Health Denton
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Aspirus Arise Health Plan
  • INSURANCE PLAN
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Oscar
  • EPO
  • HMO
  • PPO
Premera Blue Cross
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • PPO
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Texas Oncology - Denton
2600 Scripture St, Denton, TX 76201

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Enrollment Status: Available
Publish Date: January 28, 2026
Intervention Type: Drug
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
An International, Multicenter, Open-label, Randomized, Phase 3 Study of BLU-285 vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic Gastrointestinal Stromal Tumor (GIST)
Enrollment Status: Completed
Publish Date: October 06, 2022
Intervention Type: Drug
Study Drugs: Avapritinib, Regorafenib
Study Phase: Phase 3
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
A Phase III Open-label, Multicenter Trial of Avelumab (MSB0010718C) as a Third-line Treatment of Unresectable, Recurrent, or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Enrollment Status: Completed
Publish Date: November 24, 2020
Intervention Type: Drug, Other
Study Phase: Phase 3
View 6 Less Clinical Trials

22 Total Publications

Race and Disability Characteristics and Accommodation Disparities on the USMLE Step 1.
Race and Disability Characteristics and Accommodation Disparities on the USMLE Step 1.
Journal: JAMA network open
Published: September 30, 2025
Similar Doctors
Distinguished in Muscle Invasive Bladder Cancer
Dr. Suzanne Cole
Hematology
Distinguished in Muscle Invasive Bladder Cancer
Dr. Suzanne Cole
Hematology

University Of Texas Southwestern Medical Center At Dallas

3030 Waterview Pkwy, 
Richardson, TX 
 (28.5 miles away)
972-669-7070
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Suzanne Cole is a Hematologist in Richardson, Texas. Dr. Cole is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Muscle Invasive Bladder Cancer, Upper Tract Urothelial Carcinoma (UTUC), Non-Muscle Invasive Bladder Cancer, Thrombectomy, and Nephrectomy.

Distinguished in Muscle Invasive Bladder Cancer
Dr. Waddah Arafat
Oncology
Distinguished in Muscle Invasive Bladder Cancer
Dr. Waddah Arafat
Oncology

University Of Texas Southwestern Medical Center At Dallas

5200 Harry Hines Blvd, 
Dallas, TX 
 (34.1 miles away)
214-590-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Waddah Arafat is an Oncologist in Dallas, Texas. Dr. Arafat is rated as a Distinguished provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. His top areas of expertise are Testicular Cancer, Muscle Invasive Bladder Cancer, Prostate Cancer, Familial Prostate Cancer, and Orchiectomy.

Advanced in Muscle Invasive Bladder Cancer
Dr. Mary Milam
Oncology | Hematology | Internal Medicine
Advanced in Muscle Invasive Bladder Cancer
Dr. Mary Milam
Oncology | Hematology | Internal Medicine

Mary Milam, MD PA

1307 8th Ave, Ste 205, 
Fort Worth, TX 
 (35.3 miles away)
817-924-4300
Languages Spoken:
English, Spanish
See accepted insurances
Offers Telehealth

Mary Milam is a Hematologist and an Oncologist in Fort Worth, Texas. Dr. Milam is rated as an Advanced provider by MediFind in the treatment of Muscle Invasive Bladder Cancer. Her top areas of expertise are Pleuropulmonary Blastoma, Muscle Invasive Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Bone Marrow Aspiration, and Ureteroscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Jain's expertise for a condition
ConditionClose
    View All 12 Advanced Conditions
    View All 85 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile